InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 358 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec April 24, 2026 Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... November 20, 2020 Survivor’s Lucky Chance Encounter with Her Old Surgeon Leads to an... August 6, 2021 A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... June 19, 2019 Load more HOT NEWS How to Keep Your Loved One With Cancer Safe From Infection... Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in... A radical project: video game design meets cancer research Imaging Test Could Help Guide Breast Cancer Treatment Decisions
